APL-1401
- Generic Name
- APL-1401
A Phase 1b Study to Evaluate APL-1401 in Patients With Moderately to Severely Active Ulcerative Colitis
- First Posted Date
- 2023-02-24
- Last Posted Date
- 2023-09-06
- Lead Sponsor
- Jiangsu Yahong Meditech Co., Ltd aka Asieris
- Target Recruit Count
- 36
- Registration Number
- NCT05743010
- Locations
- 🇺🇸
Meridian Clinical Research, Rockville, Maryland, United States
🇺🇸Guardian Angel Research Center, Tampa, Florida, United States
🇺🇸New Hope Research Development, Corona, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath